PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Executive Summary
Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.
You may also be interested in...
Bending PDUFA’s Cost Curve: PhRMA Looking For Sustainable Program Growth
Industry feels that sufficient program management tools are in place, but a PDUFA VII negotiator says they need more time to mature.
Biosimilar User Fee Collections Drop Below Estimates, But FDA Is Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.
Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.